EG633057 inhibitors are a class of chemical compounds that exhibit a capacity to modulate biological pathways by specifically targeting their molecular substrate. These inhibitors are small molecules characterized by their ability to bind to certain target proteins or enzymes, thereby altering their activity. The specificity and affinity of EG633057 inhibitors for their molecular targets are often a result of their precise structural composition, which enables them to interact with specific binding sites or domains of their target proteins. Typically, they have a complex chemical structure that allows them to engage in non-covalent interactions such as hydrogen bonds, hydrophobic interactions, and van der Waals forces, making them highly selective in their mode of action. The physicochemical properties of these inhibitors, including their molecular weight, solubility, and stability, play a significant role in their effectiveness and bioavailability, as they dictate the ability of the inhibitors to reach their target sites within biological systems.
Structurally, EG633057 inhibitors may contain aromatic ring systems, heterocyclic cores, or functional groups that are necessary for their inhibitory function. The design and synthesis of these compounds often involve structure-activity relationship (SAR) studies to optimize their binding affinity and selectivity for their targets. Modifications to the chemical structure of EG633057 inhibitors can dramatically alter their binding properties and, consequently, their activity within biological systems. Due to their specificity, they are often utilized as research tools for probing and understanding biological pathways and processes at a molecular level. By inhibiting a particular protein or enzyme, they can be used to elucidate the role of these biomolecules in various cellular processes, making EG633057 inhibitors invaluable for mechanistic studies. Their highly specialized function and selectivity provide a platform for the exploration of biological mechanisms, with a focus on understanding molecular interactions and signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $151.00 $525.00 | 8 | |
Inhibits PLK1 by binding to the ATP pocket, leading to cell cycle arrest and mitotic spindle defects. | ||||||
BI6727 | 755038-65-4 | sc-364432 sc-364432A sc-364432B sc-364432C sc-364432D | 5 mg 50 mg 100 mg 500 mg 1 g | $150.00 $1050.00 $1665.00 $3329.00 $4382.00 | 1 | |
Binds to the ATP-binding site of PLK1, causing cell cycle arrest at the G2/M transition. | ||||||
GSK461364 | 929095-18-1 | sc-364504 sc-364504A | 10 mg 50 mg | $500.00 $1540.00 | ||
Selectively inhibits PLK1 activity, leading to mitotic arrest and apoptosis in cancer cells. | ||||||
Polo-like Kinase Inhibitor III | 660868-91-7 | sc-203202 | 500 µg | $109.00 | 1 | |
A PLK1 inhibitor that leads to cell cycle arrest at the G2/M phase by interfering with PLK1-dependent functions. | ||||||
RO-3306 | 872573-93-8 | sc-358700 sc-358700A sc-358700B | 1 mg 5 mg 25 mg | $66.00 $163.00 $326.00 | 37 | |
Inhibits PLK1, leading to mitotic arrest by preventing entry into mitosis. | ||||||
LFM-A13 | 62004-35-7 | sc-203623 sc-203623A | 10 mg 50 mg | $119.00 $670.00 | ||
A dual-action compound that inhibits both PLK1 and Bruton's tyrosine kinase, leading to impaired mitotic progression. | ||||||